The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Treatment strategies for cold AIHA
Catherine Broome, MD, Georgetown University Hospital, Washington, DC, discusses currently available treatment strategies for patients with cold autoimmune hemolytic anemia (AIHA), discussing the efficacy of rituximab alone or in combination with fludarabine or bendamustine, and commenting on the results of the Phase III Cadenza (NCT03347422) and CARDINAL (NCT03019185) studies, which demonstrated that inhibiting classical complement pathway activation with sutimlimab improves the outcomes of patients with cold agglutinin disease (CAD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
